Agri Articles
(e-Magazine for Agricultural Articles)
Volume: 06, Issue: 03 (MAY-JUNE, 2026)
Available online at http://www.agriarticles.com
©Agri Articles, ISSN: 2582-9882

TRIPS Agreement and Its Effect on Indian Patent Law

*Zainil Dalvi, Harsh Zankat, Dilip Gareja, Yuvrajsinh Barad, Harshad Makvana, Anirudh Vala and Dr. Harsiddhi Limbani
College of Agriculture, JAU, Junagadh, Gujarat, India
*Corresponding Author's email: zainildalvi@gmail.com

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is one of the most significant international agreements governing intellectual property rights (IPRs). Adopted in 1994 as part of the establishment of the World Trade Organization (WTO), TRIPS introduced minimum standards for protecting patents, trademarks, copyrights, geographical indications, industrial designs, and trade secrets. India, as a WTO member, was required to amend its patent laws to comply with TRIPS provisions. The implementation of the TRIPS Agreement brought substantial changes to the Indian patent system, particularly in pharmaceuticals, biotechnology, agriculture, and chemical industries. The Patents (Amendme nt) Acts of 1999, 2002, and 2005 transformed India's patent regime from process patents to product patents. While these reforms encouraged innovation, foreign investment, and technology transfer, they also raised concerns regarding medicine affordability, farmers' rights, and public health. This review examines the evolution of the TRIPS Agreement, its major provisions, amendments made to the Indian Patent Act, 1970, and its socio-economic impact on India.

Keywords: TRIPS Agreement, Patent Law, Intellectual Property Rights, WTO, Product Patent, Process Patent, Indian Patent Act.

Introduction

Intellectual Property Rights (IPRs) play a crucial role in promoting innovation, technological advancement, and economic development. Among various forms of IPRs, patents provide exclusive rights to inventors, encouraging investment in research and development. Before joining the World Trade Organization (WTO), India's patent regime was primarily governed by the Patents Act, 1970, which recognized only process patents for pharmaceutical and agrochemical products. This policy enabled Indian companies to manufacture affordable generic medicines using alternative production methods, making India one of the world's largest suppliers of low-cost medicines. With the establishment of the WTO in 1995, member countries became bound by the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). India was granted a transition period to amend its patent laws and fully comply with TRIPS by 2005. Consequently, significant amendments were introduced to the Indian Patent Act, fundamentally changing the country's intellectual property landscape.

TRIPS Agreement: Concept and Objectives

The TRIPS Agreement was negotiated during the Uruguay Round of the General Agreement on Tariffs and Trade (GATT) and became effective on 1 January 1995. It establishes minimum standards for the protection and enforcement of intellectual property rights among WTO member countries.

The primary objectives of TRIPS are:

- To promote innovation and technological development.
- To provide effective and adequate protection of intellectual property.

- To facilitate technology transfer between developed and developing countries.
- To reduce distortions and barriers in international trade.
- To establish a uniform legal framework for intellectual property protection.

TRIPS covers various forms of intellectual property, including patents, copyrights, trademarks, geographical indications, industrial designs, integrated circuits, and trade secrets.

Patent Provisions under the TRIPS Agreement

Article 27 of the TRIPS Agreement states that patents shall be available for any invention, whether a product or process, in all fields of technology, provided that the invention is:

- Novel
- Involves an inventive step
- Is capable of industrial application

The agreement further provides:

- A patent protection period of 20 years from the filing date.
- Equal treatment for domestic and foreign applicants.
- Protection against unauthorized making, using, selling, or importing patented products.
- Compulsory licensing under specific conditions.
- Exceptions to patentability for public morality, human health, plants, animals, and diagnostic methods.

Evolution of Indian Patent Law

India enacted the Patents Act, 1970, based largely on the recommendations of the Justice Rajagopala Ayyangar Committee. The Act emphasized public interest by encouraging affordable medicines through process patents rather than product patents.

To comply with TRIPS, India introduced three major amendments:

Patents (Amendment) Act, 1999

The first amendment introduced the "mailbox" system, allowing patent applications for pharmaceutical and agricultural chemical products to be filed during the transition period. It also provided Exclusive Marketing Rights (EMRs).

Patents (Amendment) Act, 2002

The second amendment modernized the patent system by:

- Extending patent protection to 20 years.
- Redefining patentability criteria.
- Strengthening patent enforcement.
- Establishing the Intellectual Property Appellate Board (IPAB).

Patents (Amendment) Act, 2005

The third amendment introduced product patents in pharmaceuticals, chemicals, and biotechnology. It abolished Exclusive Marketing Rights and brought India into full compliance with TRIPS.

Major Changes in Indian Patent Law after TRIPS

Aspect	Before TRIPS	After TRIPS
Pharmaceutical patents	Process patents only	Product and process patents
Patent term	7–14 years	20 years
Patentability	Limited	Expanded
Foreign patent protection	Restricted	Equal protection
Technology transfer	Limited	Encouraged
Patent filing	National	International compatibility

Impact of TRIPS on Indian Patent Law

1. Promotion of Innovation

The introduction of product patents increased investment in research and development. Indian pharmaceutical and biotechnology companies began investing significantly in innovative drug discovery and biotechnology research.

2. Growth of Foreign Direct Investment

A stronger patent regime enhanced investor confidence, attracting multinational corporations to establish research centres and manufacturing facilities in India.

3. Expansion of Pharmaceutical Research

Companies such as Sun Pharma, Dr. Reddy's Laboratories, Cipla, Lupin, and Biocon significantly increased investments in research and innovation following the implementation of TRIPS.

4. Technology Transfer

TRIPS encouraged international collaboration between Indian research institutions and multinational companies, facilitating the transfer of advanced technologies.

5. Development of Biotechnology

The biotechnology sector experienced rapid growth due to increased patent protection for biotechnological inventions, vaccines, diagnostic technologies, and genetically engineered products.

Challenges Created by TRIPS

Increase in Medicine Prices

The introduction of product patents reduced competition from generic manufacturers, leading to higher prices for patented medicines.

Access to Affordable Healthcare

Public health advocates argued that stronger patent protection could restrict access to life-saving medicines, particularly in developing countries.

Evergreening of Patents

Some multinational companies attempted to extend patent protection by making minor modifications to existing drugs. India addressed this issue through Section 3(d) of the Patent Act, which prevents patents on insignificant modifications lacking enhanced therapeutic efficacy.

Impact on Agriculture

Patent protection in biotechnology raised concerns regarding farmers' rights, seed ownership, and dependence on multinational seed companies.

Patent Litigation

The number of patent disputes increased substantially, requiring stronger judicial and administrative mechanisms for enforcement.

TRIPS Flexibilities Adopted by India

India effectively utilized several TRIPS flexibilities to balance patent protection with public interest.

Compulsory Licensing

Under Section 84 of the Indian Patent Act, compulsory licenses may be granted if:

- Public requirements are unmet.
- Patented products are unaffordable.
- The invention is not worked in India.

The landmark Natco Pharma Ltd. v. Bayer Corporation (2012) case demonstrated India's commitment to affordable medicines through compulsory licensing.

Section 3(d)

Section 3(d) prevents patenting of new forms of known substances unless they demonstrate significantly enhanced efficacy, thereby limiting patent evergreening.

Bolar Provision

Generic manufacturers are permitted to undertake research and regulatory approval before patent expiry, enabling immediate market entry after the patent term ends.

Future Prospects

India continues to balance innovation with public welfare through a carefully designed patent system. Strengthening patent examination, promoting indigenous innovation, expanding technology transfer, supporting start-ups, and preserving TRIPS flexibilities will help India maintain sustainable economic growth while protecting public health. Future reforms should encourage research without compromising access to affordable medicines and agricultural technologies.

Conclusion

The TRIPS Agreement has fundamentally transformed India's patent regime by introducing international standards for intellectual property protection. The amendments to the Indian Patent Act have strengthened innovation, attracted foreign investment, and improved global competitiveness. At the same time, concerns regarding medicine affordability, public health, agriculture, and patent monopolies remain significant. India has successfully balanced these competing interests by incorporating safeguards such as compulsory licensing and Section 3(d). Overall, the Indian patent system demonstrates that intellectual property protection and public interest can coexist through carefully designed legislation and effective implementation.

References

1. Basheer, S. (2005). *India's Tryst with TRIPS: The Patents (Amendment) Act, 2005*. Indian Journal of Law and Technology.
2. Cornish, W., Llewelyn, D., & Aplin, T. (2019). *Intellectual Property: Patents, Copyright, Trade Marks and Allied Rights*.
3. Government of India. (1970). *The Patents Act, 1970*. Ministry of Commerce and Industry.
4. Government of India. (2005). *The Patents (Amendment) Act, 2005*. Ministry of Commerce and Industry.
5. Narayanan, P. (2017). *Patent Law* (4th ed.). Eastern Law House.
6. World Intellectual Property Organization (WIPO). (2023). *Understanding Patents*.
7. World Trade Organization (WTO). (1994). *Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)*.
8. WTO. (2023). *TRIPS and Public Health*.